Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting
June 24th, 2008 by adminAlexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.
More: continued here
Posted in Uncategorized |